Company Overview and News

5
How To Avoid Losing Stocks

2018-09-17 seekingalpha
Most large losers had clear characteristics in place before their declines accelerated that would have allowed traders or investors to avoid them.
ABX HRB KOR KGI KGI.DB.A KGI.DB KL CORVF ABX

 
Coeur Mining: Still Just A Call Option On Gold And Silver Prices

2018-09-13 seekingalpha
Coeur Mining reported a positive sustaining free cash flow in H1 using $16.50 per ounce silver and $1250 per ounce gold.
CDE KOR CDEUW PSPGF CORVF

1
Bullfrog Gold’s New Exploration Targets and Leach Test Results at its Nevada Project

2018-08-21 globenewswire
Grand Junction, Colorado, Aug. 21, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE LLC -- Bullfrog Gold Corp (OTCQB:BFGC) (“BFGC” or the “Company”) is pleased to announce new exploration targets with related claim staking, increased gold recoveries from leach tests and the submittal of an environmental permit application at its Bullfrog Project (Project). The Company controls the commanding land and resource positions in the Bullfrog mine area, which is 120 miles NW of Las Vegas and 4 miles west of Beatty, Nevada.
CDE AULGF KOR BFGC AU CDEUW AGG PSPGF CORVF

1
AngloGold Ashanti Limited (AU) CEO Srinivasan Venkatakrishnan on Q2 2018 Results - Earnings Call Transcript

2018-08-20 seekingalpha
AngloGold Ashanti Limited (NYSE:AU) Q2 2018 Results Earnings Conference Call August 20, 2018 9:00 AM ET
AULGF RNSGF KOR REN AU AGG CORVF

1
Corvus Gold Drills 109.7 Metres @ 1.4 g/t Gold (including 54.8m @ 1.86 g/t gold), West Zone Stepout, Mother Lode Project, Nevada

2018-07-12 globenewswire
VANCOUVER, British Columbia, July 12, 2018 (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus” or the “Company”) - (TSX:KOR) (OTCQX:CORVF) announces it has received additional results from its resource expansion drill program on the western extension of the 100% owned Mother Lode deposit (Figure 1 & 2). The most recent result, hole ML18-068, the western-most hole drilled to date, returned 109.73 metres @ 1.
AULGF KOR ABX AU AGG ABX CORVF

4
Corvus Gold Closes $4.5M Financing with Strategic Investor to Advance Its Mother Lode Project Through 2019

2018-06-07 globenewswire
VANCOUVER, British Columbia, June 07, 2018 (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus” or the “Company”) - (TSX:KOR) (OTCQX:CORVF) announces it has completed a CAD $4,500,002 private placement (the “Private Placement”). Pursuant to the Private Placement, the Company issued 1,730,770 common shares at a price of CAD $2.60 to a key strategic shareholder. No warrants were issued. Proceeds of the financing will fund the planned Phase Three 30,000 metre exploration drill program at Mother Lode project through 2018-19.
KOR CORVF

15
Renaissance Gold Drilling Update

2018-05-01 accesswire
VANCOUVER, BC / ACCESSWIRE / May 1, 2018 / Renaissance Gold Inc. TSX.V: REN ("RenGold" or the "Company") expects exploration drilling programs on at least seven of its partner-funded projects during 2018. Some of that drilling is ongoing and other programs are planned for later in the year. The following is an update on two of these projects already underway.
AULGF RNSGF KOR REN AU AGG S2R PSPGF CORVF

4
Corvus Gold Continues to Expand Deposit West, Drill Results Include 33.5 Metres @ 2.2 g/t Gold, Mother Lode Project, Nevada

2018-04-25 globenewswire
VANCOUVER, British Columbia, April 25, 2018 (GLOBE NEWSWIRE) -- Corvus Gold Inc. (“Corvus” or the “Company”) - (TSX:KOR) (OTCQX:CORVF) announces it has received results from three stepout holes in the southwest extension of the Mother Lode deposit (Figure 1) highlighted by hole ML18-053 which returned 33.5m @ 2.2 g/t gold including 19.8m @ 3.3 g/t gold. Assay results returned encouraging intercepts showing continued expansion of the deposit which is nearly all oxide to the bottom of the holes (Table 1).
KOR CORVF

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

16h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

17h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

19h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

Silicon Investor Message Boards

This table lists all message boards related to TSX:KOR / Corvus Gold Inc on message board site Silicon Investor.

Akorn Inc. Akorn Inc. Akorn Inc. CDMA, Qualcomm, [Hong Kong, Korea, LA] THE MARKET TEST! CDMA, Qualcomm, [Hong Kong, Korea, LA] THE MARKET TEST! CDMA, Qualcomm, [Hong Kong, Korea, LA] THE MARKET TEST!
KERMu0027S KORNER KERMu0027S KORNER KERMu0027S KORNER Boycott China Until It Squeezes the North Korean Regime to r Boycott China Until It Squeezes the North Korean Regime to r Boycott China Until It Squeezes the North Korean Regime to r
Korea Telecom - KTC Korea Telecom - KTC Korea Telecom - KTC Amkor Technology Inc (AMKR) Amkor Technology Inc (AMKR) Amkor Technology Inc (AMKR)
Korea Korea Korea Korea Electric Power Corp. Korea Electric Power Corp. Korea Electric Power Corp.
KF: Korea Fund KF: Korea Fund KF: Korea Fund Far East Markets - Taiwan, Korea, Hong Kong, China and India Far East Markets - Taiwan, Korea, Hong Kong, China and India Far East Markets - Taiwan, Korea, Hong Kong, China and India